A carregar...
Publicação
Editorial: FGF21 as a therapeutic target for obesity and insulin resistance: from rodent models to humans
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 269.16 KB | Adobe PDF |
Orientador(es)
Resumo(s)
Obesity is a global pandemic that requires the urgent development of therapies and
prevention strategies. To define new pharmacologic therapies or nutritional approaches it
is mandatory to find new targets. Fibroblast growth factor 21 (FGF21) is considered a
potential target to treat obesity, due to its favorable metabolic activity, signalling pathways
and regulatory mechanisms. It is well-documented that FGF21 is induced by a wide range
of biological stress conditions and a key signal that communicates and coordinates the
physiologic response to restore the metabolic homeostasis in different tissues (1). FGF21 is
elevated in pathological conditions such as obesity, insulin resistance, or fatty liver disease
where an impairment of its signalling has been described (2). On the other hand, FGF21
analogues tested in overweight/obese patients with type 2 diabetes or NAFLD/NASH can
reduce dyslipidaemia and steatosis, but improvements in glycaemic control or body weight
were not globally restored (3). This suggests that pharmacologic effects of FGF21 are
different from its physiological effects. In this Research Topic “FGF21 as a therapeutic
target for obesity and insulin resistance: from rodent models to humans”, we include
publications related to new advances involving FGF21, its signalling pathway, and its
potential as a target to treat obesity
Descrição
Palavras-chave
FGF21 (fibroblast growth factor 21) Obesity Insulin resistance Metabolism Beta-Klotho
Contexto Educativo
Citação
Editora
Frontiers Media